You are here: Industry Insights > billion

News List

Which ADCs Are Favored by Foreign Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
China's Innovative Drugs Hunt for Billion Dollar Molecule Xiaobin
December 20, 2024
The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.
From Ruxolitinib to Upadacitinib, the USD 5 Billion Blue Ocean Market Ushers a Fierce Battle of JAK Inhibitors Spuer 203
May 06, 2024
Medical System from Incyte has initiated Phase III clinical trials of vitiligo in China.
With Whole Line Reduction or R&D Difficulties, Projects of Billions of Dollars Are Stranded - Analysis on Transnational Pharmaceutical Companies Terminating R&D Projects in H1 of the Year PharmaSources/Spuer 203
August 28, 2023
Sales volume of Dupixent reaching USD 5.35 billion in H1 of the year, setting off a R&D boom of IL-4R in China PharmaSources/Yefenghong
August 28, 2023
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.
What is the Confidence of this Pharmaceutical Company To Target its Sales Peak of CNY 10 Billion? Xiaobin/PharmaSources
August 07, 2023
Recently, at Everest Medicines' investor exchange activities, the management led by CEO Luo Yongqing put forward the target of "realizing the marketing of four commercial products in a short time, with a sales peak of CNY 10 billion".
More ADCs made in China, Led by Kelun Pharmaceutical, Expanding into the World Market with a Total Transaction Amount of over USD 20 billion Yi/PharmaSources
June 06, 2023
More ADCs made in China, led by Kelun Pharmaceutical, expanding into the world market with a total transaction amount of over USD 20 billion.
Global ICIs Market Exceeds USD 30 Billion in 2021, with its Number and Indications Approved Entering an Outbreak Period Yi
April 11, 2022
Lately, Opdualag, a fixed-dose compound preparation of BMS consisting of LAG-3 inhibitor relatlimab and PD-1 monoclonal antibody nivolumab, was approved by FDA for the treatment of adults and pediatric patients aged 12 years and older with unresectable or
Bivalent HPV Vaccine of Walvax Approved for Marketing: Who Will be the Leader of the Market Valuing RMB 100 billion? Yefenghong
April 11, 2022
Bivalent HPV Vaccine of Walvax Approved for Marketing: Who Will be the Leader of the Market Valuing RMB 100 billion?